Linde AG / Key word(s): Change of Personnel 27.09.2013 10:45 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- The Supervisory Board of Linde AG, in its meeting today, has appointed Dr Wolfgang Büchele (54) as member of the Executive Board effective 1 May 2014 and designated CEO. Following the annual general meeting on 20 May 2014, Büchele will take over the role as CEO from Prof. Dr Wolfgang Reitzle (64) whose appointment will end then due to reaching the age limit. 'With Dr Wolfgang Büchele we have found an excellent industry expert and internationally experienced manager. We are very pleased to have won him for Linde,' said Dr Manfred Schneider, Chairman of the Supervisory Board of Linde AG. 'He is a skilled strategist and true insider of the chemical industry. With his wealth of experience he fulfils all prerequisites to further advance Linde in its successful development, excellently managed by Prof. Wolfgang Reitzle, and ensure a seamless and sustainable continuation on this path.' 'It is a great honour for me to be given the opportunity and also challenge to take over the reigns of Linde,' said Dr Wolfgang Büchele. 'I have been following the rapid and very positive development of the company during the past years and now look forward to actively shaping its future.' Wolfgang Büchele is CEO of the Finnish chemical company Kemira since April 2012. From 2009 to 2011 he was CEO of the Hungarian chemical company BorsodChem. Before that Büchele was 20 years at BASF in various responsible positions. In addition, the Supervisory Board has decided to extend the term of Sanjiv Lamba (49) by five years until March 2019. Lamba is member of the Executive Board since March 2011. He is responsible for the gases business in Greater China, South & East Asia and the South Pacific as well as for Asia Joint Ventures and the Electronic gases business. --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: For further information: Media Uwe Wolfinger Tel: +49.89.35757-1320 Matthias Dachwald Tel: +49.89.35757-1333 Investor Relations Dr Dominik Heger Tel: +49.89.35757-1334 Lisa Tilmann Tel: +49.89.35757-1328 27.09.2013 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Linde AG Klosterhofstra�e 1 80331 München Germany Phone: +49.89.35757-01 Fax: +49.89.35757-1075 E-mail: info@linde.com Internet: www.linde.de ISIN: DE0006483001 WKN: 648300 Indices: DAX Listed: Regulierter Markt in Berlin, Düsseldorf, Frankfurt (Prime Standard), Hamburg, München, Stuttgart; Freiverkehr in Hannover; Terminbörse EUREX; SIX End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Linde AG: Dr Wolfgang Büchele to become new
Top 10 Most Recent News Articles
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation
Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...
Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data
Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...
Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight
A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...
Continue Reading
NARUTO Card Game Set for June 2027 Global Launch
Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...
Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight
First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...
Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps
Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...
Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal
A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...
Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity
Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...
Continue Reading
AI Drives Major Time Savings in Endoscopy Tech
AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...
Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances
A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...
Continue ReadingTop 5 Most Recently Viewed Articles
Chart Industries Transitions to New Leadership in Upcoming Merger
Chart Industries Announces Leadership Change Chart Industries (NYSE: GTLS) is taking significant steps toward a future transition as CEO Jill Evanko has announced plans to assume a senior advisor role starting in early 2026. This change comes as she prepares to take on a new executive opportunity within a privately owned company. Evanko has been essential in steering the...
Continue Reading
Understanding Debtors: Insights into Realkredit Danmark A/S
Understanding Debtors: Key Insights from Realkredit Danmark A/S At the heart of any effective financial institution is a reliable understanding of its debtors. Realkredit Danmark A/S, a prestigious name in the financial landscape, recently made available a detailed breakdown of its debtors. This information is crucial for various stakeholders, including investors,...
Continue Reading
Cryptocurrency Market Update: Bitcoin Droops under $59K with ETF Inflows Soaring
Bitcoin's Recent Performance The cryptocurrency market has been lively lately, especially with Bitcoin recently falling below the $59,000 threshold. Investors had been optimistic, especially since the cryptocurrency saw a remarkable $436 million in net ETF inflows just last week. This significant influx signals that institutional interest in cryptocurrencies is still...
Continue Reading
Enhancing Specialized Care for ARFID Treatment with Emily Program
Introduction to The Emily Program and ARFID The Emily Program is making significant strides in specialized care for individuals with Avoidant/Restrictive Food Intake Disorder (ARFID). This condition, often misunderstood, has recently begun to garner more attention from healthcare experts. In response to this need, The Emily Program is offering advanced treatment...
Continue Reading
Investigation of Alleged Securities Fraud at 3D Systems Unfolds
Overview of Legal Actions Against 3D Systems Corporation Recently, investors in 3D Systems Corporation have found themselves entangled in a potential securities fraud lawsuit. This case serves as a cautionary tale, highlighting the importance of transparency and integrity in corporate communication. The allegations stem from assertions that the company made misleading...
Continue Reading